

# Kees van Gool

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3077480/publications.pdf>

Version: 2024-02-01

57  
papers

812  
citations

516710

16  
h-index

552781

26  
g-index

57  
all docs

57  
docs citations

57  
times ranked

1128  
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. <i>International Journal for Quality in Health Care</i> , 2015, 27, 137-46.	1.8	115
2	Understanding the Costs of Care for Cystic Fibrosis: An Analysis by Age and Health State. <i>Value in Health</i> , 2013, 16, 345-355.	0.3	71
3	Who's Getting Caught? An Analysis of the Australian Medicare Safety Net. <i>Australian Economic Review</i> , 2009, 42, 143-154.	0.7	32
4	Bleeding Hearts, Profiteers, or Both: Specialist Physician Fees in an Unregulated Market. <i>Health Economics (United Kingdom)</i> , 2017, 26, 528-535.	1.7	32
5	Delays in access to affordable medicines: putting policy into perspective. <i>Australian Health Review</i> , 2012, 36, 412.	1.1	29
6	Measuring horizontal inequity in healthcare utilisation: a review of methodological developments and debates. <i>European Journal of Health Economics</i> , 2020, 21, 171-180.	2.8	28
7	Economic evaluation of cystic fibrosis screening: A review of the literature. <i>Health Policy</i> , 2008, 85, 133-147.	3.0	27
8	Decision makers' perceptions of health technology decision making and priority setting at the institutional level. <i>Australian Health Review</i> , 2008, 32, 520.	1.1	27
9	Adapting portfolio theory for the evaluation of multiple investments in health with a multiplicative extension for treatment synergies. <i>European Journal of Health Economics</i> , 2002, 3, 47-53.	2.8	24
10	International comparison of health spending and utilization among people with complex multimorbidity. <i>Health Services Research</i> , 2021, 56, 1317-1334.	2.0	24
11	Cost-effectiveness of carrier screening for cystic fibrosis in Australia. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 281-287.	0.7	22
12	Differences in health care spending and utilization among older frail adults in high-income countries: ICCONIC hip fracture persona. <i>Health Services Research</i> , 2021, 56, 1335-1346.	2.0	22
13	The hidden costs of drug and alcohol use in hospital emergency departments. <i>Drug and Alcohol Review</i> , 2016, 35, 359-366.	2.1	21
14	Horizontal inequity in the utilisation of healthcare services in Australia. <i>Health Policy</i> , 2020, 124, 1263-1271.	3.0	20
15	A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007182.	3.0	19
16	How common is multiple general practice attendance in Australia?. , 2018, 47, 289-296.		18
17	Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. <i>European Journal of Health Economics</i> , 2015, 16, 709-717.	2.8	17
18	The Distribution of Household Health Expenditures in Australia*. <i>Economic Record</i> , 2008, 84, S99.	0.4	16

#	ARTICLE	IF	CITATIONS
19	Nursing Takes Time: Workload Associated With Administering Cancer Protocols. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 735-741.	0.6	16
20	Inequity in physician visits: the case of the unregulated fee market in Australia. <i>Social Science and Medicine</i> , 2020, 255, 113004.	3.8	16
21	Economic Evidence at the Local Level. <i>Pharmacoeconomics</i> , 2007, 25, 1055-1062.	3.3	15
22	Resource allocation and health technology assessment in Australia: Views from the local level. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 134-140.	0.5	15
23	The Rise and Fall in Out-of-Pocket Costs in Australia: An Analysis of the Strengthening Medicare Reforms. <i>Health Economics (United Kingdom)</i> , 2017, 26, 962-979.	1.7	14
24	Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care Study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 178-186.	1.1	13
25	Evaluating the Impact of Hospital Based Drug and Alcohol Consultation Liaison Services. <i>Journal of Substance Abuse Treatment</i> , 2016, 68, 36-45.	2.8	13
26	Differences in health outcomes for high-need, high-cost patients across high-income countries. <i>Health Services Research</i> , 2021, 56 Suppl 3, 1347-1357.	2.0	13
27	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. <i>Value in Health</i> , 2015, 18, 1098-1104.	0.3	11
28	Targeting services to reduce social inequalities in utilisation: an analysis of breast cancer screening in New South Wales. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 12.	2.2	10
29	International comparison of spending and utilization at the end of life for hip fracture patients. <i>Health Services Research</i> , 2021, 56, 1370-1382.	2.0	9
30	Modelling the Relationship between Child Abuse and Long-Term Health Care Costs and Wellbeing: Results from an Australian Community-Based Survey. <i>Economic Record</i> , 2013, 89, 300-318.	0.4	8
31	Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 625-634.	2.1	8
32	Physician pricing behavior: Evidence from an Australian experiment. <i>Journal of Economic Behavior and Organization</i> , 2019, 161, 20-34.	2.0	8
33	The business of integrated care: implementing new models of care in a fee-for-service setting. <i>Journal of Integrated Care</i> , 2018, 26, 16-28.	0.5	7
34	Inequity in healthcare use among the indigenous population living in non-remote areas of Australia. <i>Public Health</i> , 2020, 186, 35-43.	2.9	7
35	Paying for value: options for value-based payment reform in Australia. <i>Australian Health Review</i> , 2022, 46, 129-133.	1.1	7
36	Supplier-induced demand for urgent after-hours primary care services. <i>Health Economics (United Kingdom)</i> , 2022, 42, 1071-1086.	1.7	6

#	ARTICLE	IF	CITATIONS
37	How much of Australia's health expenditure is allocated to general practice and primary healthcare?. Australian Journal of General Practice, 2021, 50, 673-678.	0.8	6
38	Within and across country variations in treatment of patients with heart failure and diabetes. Health Services Research, 2021, 56, 1358-1369.	2.0	5
39	A methodology for identifying high-need, high-cost patient personas for international comparisons. Health Services Research, 2021, 56, 1302-1316.	2.0	5
40	Is low-priced primary care bad for quality? Evidence from Australian general practice. Applied Economics, 2018, 50, 475-491.	2.2	4
41	The prevalence of persistence and related health status: An analysis of persistently high healthcare costs in the short term and medium term. Social Science and Medicine, 2018, 211, 147-156.	3.8	4
42	Does more investment in primary care improve health system performance?. Health Policy, 2021, 125, 717-724.	3.0	4
43	Rates of Low-Value Service in Australian Public Hospitals and the Association With Patient Insurance Status. JAMA Network Open, 2021, 4, e2138543.	5.9	4
44	Chemotherapy Administration. Pharmacoeconomics, 2012, 30, 1173-1186.	3.3	3
45	Can administrative data be used to measure chemotherapy side effects?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 215-222.	1.4	3
46	Accommodation payment plans in residential aged care: The impact of consumer choice. Australasian Journal on Ageing, 2020, 39, e103-e109.	0.9	3
47	Private finance publicly subsidized: the case of Australian health insurance. , 2020, , 41-64.		3
48	Diagnosis and prognosis of Australia's health information for evidence-based policy. Journal of Health Services Research and Policy, 2002, 7, 40-45.	1.7	2
49	SURGEONS' VIEWS OF HEALTH TECHNOLOGY ASSESSMENT IN AUSTRALIA: ONLINE PILOT SURVEY. International Journal of Technology Assessment in Health Care, 2013, 29, 309-314.	0.5	2
50	Health care use in response to health shocks: Does socioeconomic status matter?. Health Economics (United Kingdom), 2021, 30, 3032-3050.	1.7	2
51	Improving outcomes for marginalised rural families through a care navigator program. Health Promotion Journal of Australia, 2021, 32, 285-294.	1.2	1
52	Health care cost of crusted scabies in Aboriginal communities in the Northern Territory, Australia. PLoS Neglected Tropical Diseases, 2022, 16, e0010288.	3.0	1
53	1437Rates of low value care in NSW public hospitals: variation between public and private inpatients. International Journal of Epidemiology, 2021, 50, .	1.9	0
54	Letters to the Editor: Can we deny patients expensive drugs?. Australian Prescriber, 2007, 30, 59-63.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Delays in access to affordable medicines: putting policy into perspective – authors’ response. Australian Health Review, 2014, 38, 16.	1.1	0
56	Failure to access prescribed pharmaceuticals by older patients with chronic conditions. Australian Health Review, 2020, 44, 270.	1.1	0
57	Evaluation of the Victorian Healthy Homes Program: protocol for a randomised controlled trial. BMJ Open, 2022, 12, e053828.	1.9	0